Development and evaluation of a live-attenuated novel duck reovirus vaccine strain E232-P100 conferring complete protection in ducklings

IF 2.8 2区农林科学 Q3 MICROBIOLOGY

Veterinary microbiology Pub Date : 2026-03-01 Epub Date: 2026-02-03 DOI:10.1016/j.vetmic.2026.110929

Siying Fang, Chenchen Xu, Jiabin Zhang, Haiyang Yin, Wenjian Liu, Biao Xu, Jiajia Li, Phoo Eikari Kyaw, Shuhui Liu, Suquan Song, Liping Yan

{"title":"Development and evaluation of a live-attenuated novel duck reovirus vaccine strain E232-P100 conferring complete protection in ducklings","authors":"Siying Fang, Chenchen Xu, Jiabin Zhang, Haiyang Yin, Wenjian Liu, Biao Xu, Jiajia Li, Phoo Eikari Kyaw, Shuhui Liu, Suquan Song, Liping Yan","doi":"10.1016/j.vetmic.2026.110929","DOIUrl":null,"url":null,"abstract":"<div><div>Novel duck reovirus (NDRV) is a major pathogen that causes immunosuppression and secondary infections in ducklings, resulting in elevated mortality and severe economic losses to the global duck industry. However, there is currently no licensed vaccine available in China for the effective prevention and control of NDRV infections. To effectively control NDRV outbreaks, we developed a live-attenuated vaccine candidate against NDRV by serially passaging the NDRV E232 strain in specific-pathogen-free (SPF) chicken embryos and DF-1 cells. The resulting E232-P100 strain replicated efficiently in DF-1 cells, with viral titers reaching up to 10<sup>7.0</sup> TCID<sub>50</sub>/0.2 mL. No clinical symptoms or pathological lesions were observed in two-day-old Cherry Valley ducklings inoculated with E232-P100, and no virulence reversion was observed after five rounds of in vivo back-passage in ducklings. The minimum protective dose of the attenuated E232-P100 strain was 10<sup>3.0</sup> TCID<sub>50</sub>/0.2 mL. Evaluation of the onset of immune protection showed that complete protection was achieved by 5 days post-vaccination. Comparative genomic analysis revealed 18 amino acid substitutions between E232-P100 and the parental E232 strain, including three within the σC protein that are potentially associated with attenuation. Collectively, the E232-P100 strain represents a safe, stable, and highly protective live attenuated vaccine candidate for the prevention of NDRV infection, providing a promising foundation for the development of effective prevention strategies against NDRV epidemics in waterfowl populations.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"314 ","pages":"Article 110929"},"PeriodicalIF":2.8000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S037811352600060X","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Novel duck reovirus (NDRV) is a major pathogen that causes immunosuppression and secondary infections in ducklings, resulting in elevated mortality and severe economic losses to the global duck industry. However, there is currently no licensed vaccine available in China for the effective prevention and control of NDRV infections. To effectively control NDRV outbreaks, we developed a live-attenuated vaccine candidate against NDRV by serially passaging the NDRV E232 strain in specific-pathogen-free (SPF) chicken embryos and DF-1 cells. The resulting E232-P100 strain replicated efficiently in DF-1 cells, with viral titers reaching up to 10^7.0 TCID₅₀/0.2 mL. No clinical symptoms or pathological lesions were observed in two-day-old Cherry Valley ducklings inoculated with E232-P100, and no virulence reversion was observed after five rounds of in vivo back-passage in ducklings. The minimum protective dose of the attenuated E232-P100 strain was 10^3.0 TCID₅₀/0.2 mL. Evaluation of the onset of immune protection showed that complete protection was achieved by 5 days post-vaccination. Comparative genomic analysis revealed 18 amino acid substitutions between E232-P100 and the parental E232 strain, including three within the σC protein that are potentially associated with attenuation. Collectively, the E232-P100 strain represents a safe, stable, and highly protective live attenuated vaccine candidate for the prevention of NDRV infection, providing a promising foundation for the development of effective prevention strategies against NDRV epidemics in waterfowl populations.

查看原文本刊更多论文

鸭呼肠孤病毒新型减毒活疫苗E232-P100株的研制与评价，对雏鸭具有完全保护作用。

新型鸭呼肠孤病毒（NDRV）是引起雏鸭免疫抑制和继发性感染的主要病原体，导致死亡率升高，并给全球鸭业造成严重的经济损失。然而，中国目前还没有获得许可的疫苗来有效预防和控制NDRV感染。为了有效控制NDRV的爆发，我们将NDRV E232毒株在SPF鸡胚和DF-1细胞中连续传代，开发了NDRV减毒活疫苗候选株。所得E232-P100菌株在DF-1细胞中高效复制，病毒滴度高达107.0 TCID50/0.2 mL。接种E232-P100 2日龄樱桃谷雏鸭未见临床症状和病理病变，5轮体内回传后雏鸭毒力未见逆转。E232-P100减毒株的最低保护剂量为103.0 TCID50/0.2 mL。免疫保护开始的评估表明，免疫接种后5天达到完全保护。比较基因组分析显示，E232- p100与亲本E232菌株之间存在18个氨基酸替换，其中3个位于σC蛋白内，可能与衰减有关。综上所述，E232-P100毒株是一种安全、稳定、高保护性的NDRV减毒活疫苗候选株，可用于预防NDRV在水禽种群中的流行，为制定有效的NDRV预防策略奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary microbiology 农林科学-兽医学

CiteScore

5.90

自引率

6.10%

发文量

221

审稿时长

52 days

期刊介绍： Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal. Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge. Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.